Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
215.98
+8.15 (3.92%)
Oct 30, 2026, 4:00 PM EDT - Market closed
Jazz Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 22 analysts polled by S&P Global, Jazz Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $295.36. The average 1-year stock price forecast is 36.75% higher than the current stock price, while the lowest is $225 (+4.18%) and the highest is $337 (+56.03%).
Price Target: $295.36 (+36.75%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Jazz Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 11 | 11 | 13 | 13 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 1 | 1 | 1 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 20 | 20 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Reiterates $276 → $300 | Buy | Reiterates | $276 → $300 | +38.90% | Oct 28, 2026 |
| UBS | UBS | Buy Maintains $337 | Buy | Maintains | $337 | +56.03% | Oct 28, 2026 |
| Citi | Citi | Buy Maintains $325 | Buy | Maintains | $325 | +50.48% | Oct 27, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $322 → $314 | Buy | Reiterates | $322 → $314 | +45.38% | Oct 21, 2026 |
| Needham | Needham | Buy Reiterates $310 | Buy | Reiterates | $310 | +43.53% | Oct 16, 2026 |
Financial Forecast
Revenue This Year
4.74B
from 4.27B
Increased by 11.00%
Revenue Next Year
5.02B
from 4.74B
Increased by 5.89%
EPS This Year
15.63
from 8.38
Increased by 86.57%
EPS Next Year
25.00
from 15.63
Increased by 59.94%
EPS and Forward PE are based on non-GAAP adjusted numbers.